Sensus Healthcare (SRTS) to Release Quarterly Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS) will likely be posting its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Sensus Healthcare to post earnings of ($0.1250) per share and revenue of $5.3230 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Sensus Healthcare Trading Down 0.6%

Shares of Sensus Healthcare stock traded down $0.03 on Tuesday, reaching $3.94. 19,960 shares of the company were exchanged, compared to its average volume of 77,413. The stock has a fifty day moving average price of $4.13 and a 200-day moving average price of $4.14. The firm has a market capitalization of $64.78 million, a price-to-earnings ratio of -8.28 and a beta of 1.19. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $5.92.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SRTS. Geode Capital Management LLC increased its holdings in shares of Sensus Healthcare by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after acquiring an additional 3,766 shares during the last quarter. Jane Street Group LLC acquired a new stake in Sensus Healthcare in the 4th quarter valued at approximately $79,000. State Street Corp lifted its position in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after acquiring an additional 3,400 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth approximately $219,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth approximately $513,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Maxim Group cut their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Alliance Global Partners assumed coverage on Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 target price on the stock. Finally, Wall Street Zen lowered Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.88.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.